Tag Archives: California

State Legislation Needed For Substitution of Interchangeable Biologics

Copyright sanofi pasteur

A great deal of the media coverage relating to California’s Senate Bill 598  neglects to mention a key issue in the biosimilars debate. This bill – or legislation similar to it – is essential to allow for the eventual substitution of interchangeable biologic therapies in the state of California. State laws governing prescription drug substitution were written before the advent of biosimilars and do not take the complexity of biologics into account. California, along with Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

California Continues Responsible Support for Interchangeability of Biologic Drugs

State Capitol

Yesterday, California’s State Assembly Committee on Appropriations took another decisive step when they unanimously voted in support of the revised SB 598 by recommending it back to the full Assembly after minor modifications. This is another important step taken by the California State Legislature to ensure patients and physicians who are managing chronic conditions are made fully aware of which biologic drug is ultimately administered by the pharmacist. When battling a serious disease, patients, physicians Read More >

Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , ,

CHI Program to Offer Tips for Acquiring Pipeline Funding

AB23475

Biomedical innovations rely largely on scientific breakthroughs, which in turn happen through well-structured research programs. CHI’s Pipeline for Life  will focus on what characterizes successful basic research models in the 21st century, during a time when researchers are experiencing declining governmental funding for science research. Collaboration between industry and academic partners will be necessary to keep the biomedical ecosystem healthy, and the industry’s pipeline full of innovation. This half-day program will explore the strategies and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , ,

California Biomedical Companies Cite Lack Of Funding As Major Concern

Investment

As I have mentioned in past blog posts, the U.S. bioscience industry has demonstrated stability through turbulent economic times. While not immune from the recession, this industry generally fared much better than the overall economy and has remained a net a job generator. In April of 2012, the White House released the National Bioeconomy Blueprint noting that bioscience industries are “a large and rapidly growing segment of the world economy that provides substantial public benefit.” Read More >

Business and Investments  |  Leave a comment  |  Email This Post
Tags: , , ,

BayBio Announces Lifetime Achievement DiNA Award Recipient

BayBio

Dr. Michael Hunkapiller has been named BayBio’s 2011 Lifetime Achievement DiNA Award recipient. He will be honored on Thursday, November 3rd, at the 2011 Pantheon Awards Ceremony, an annual program hosted by BayBio, a life science trade association representing the industry in Northern California. From the invention of the DNA sequencer during his days at Caltech, to the introduction of first automated DNA sequencer in 1986 and the realization of the Human Genome Mapping Project Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , ,